HC Wainwright & Co. Reiterates Buy on Intercept Pharma, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Intercept Pharma (NASDAQ:ICPT) and maintained a price target of $19.
August 04, 2023 | 2:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intercept Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $19.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Intercept Pharma. The maintained price target of $19 also indicates the firm's confidence in the stock's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100